CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases

BASEL, Switzerland & ILLKIRCH GRAFFENSTADEN, France--(BUSINESS WIRE)--CRISPR Therapeutics and Anagenesis Biotechnologies today announced a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases. The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cell